Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2019-09-12 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Change in substantial holding 2 pages 123.4KB
Regulatory Filings
2019-09-12 English
Opthea Presents Positive Phase 2b Data at EURETINA Congress 3 pages 79.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 6 September 2019 from Opthea Limited presenting positive clinical trial data from a Phase 2b study of OPT-302 for wet AMD. It details clinical trial results, safety data, and scientific analysis presented at a medical congress (EURETINA). The document is a press release announcing clinical trial outcomes rather than a formal financial report, regulatory filing, or investor presentation. It does not contain financial statements, management discussion, or regulatory certifications. It is not an earnings release or annual/interim report. The content focuses on clinical data presentation and company updates related to drug development progress. Therefore, the best fitting category is a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2019-09-05 English
Opthea Presentation for EURETINA Congress 17 pages 1.0MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation of clinical trial results for Opthea Limited's OPT-302 Phase 2b study in wet AMD. It includes study design, patient demographics, efficacy outcomes, safety data, and conclusions. The content is structured as a presentation with slides, charts, and detailed explanations of trial endpoints and results. There is no indication that this is an official regulatory filing, annual or interim financial report, earnings release, or management discussion. The document is clearly intended for investors or stakeholders to communicate clinical trial progress and results, which fits the definition of an Investor Presentation (IP). The length and detail confirm it is the full presentation, not just an announcement or summary. Therefore, the appropriate classification is Investor Presentation (IP) with high confidence.
2019-09-05 English
Opthea Ph2b of OPT-302 in wAMD to be Presented at EURETINA 3 pages 73.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 4 September 2019 from Opthea Limited announcing that data from its Phase 2b clinical study of OPT-302 in Wet AMD will be presented at the EURETINA Congress. It describes the study design, outcomes, and the upcoming presentation event. The document is a public announcement about the presentation of clinical trial results rather than the presentation itself or a detailed financial or regulatory report. It does not contain financial statements, management discussion, or regulatory certifications. The document is longer than 5,000 characters but is clearly an announcement of a presentation of clinical data, not a financial or regulatory filing. Therefore, it fits best into the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2019-09-03 English
Change in substantial holding 3 pages 97.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, Section 671B, which is a notice of change of interests of a substantial holder. It details changes in voting power and shareholdings of BVF Partners LP and associated entities in Opthea Limited. The content focuses on share transactions and changes in substantial shareholdings, with no financial performance data, earnings, or management commentary. This type of filing corresponds to notifications about major shareholding changes, which aligns with the category 'Major Shareholding Notification' (MRQ). The document length is substantial and contains detailed shareholding changes, confirming it is not a brief announcement or a report publication notice.
2019-08-28 English
Change in substantial holding 2 pages 61.4KB
Regulatory Filings
2019-08-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.